Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BIOGEN INC.BIIB · Entity 1675 | EVP Pharmaceutical Oper & Tech | March 01, 2019 | March 05, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BIOGEN INC.
Report date March 01, 2019 · Filed March 05, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 7,234.631 |
Ending reported balance
After 2019-03-01 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2019-03-01 · Tax withholding · Disposed 405 · Balance 6,919.631 Row 2 · 2019-03-01 · Exercise / conversion · Acquired 568 · Balance 7,487.631 Row 3 · 2019-03-01 · Tax withholding · Disposed 253 · Balance 7,234.631 |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2019-03-01 | Direct | 280 |
Reported balance
After 2019-03-01 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2019-03-01 · Exercise / conversion · Disposed 568 · Balance 280 F1: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2019-03-01 | Direct | 0 |
Reported balance
After 2019-03-01 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2019-03-01 · Other · Disposed 280 · Balance 0 F2: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested. F1: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). |
Filing footnotes · ownership attribution and instrument terms
F1: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]).
F2: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 01, 2019 Filed Mar 5, 2019 21:17 UTC | BIOGEN INC. BIIB · Entity 1675 | OtherRestricted Stock Unit · Derivative | 280 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-009924 · form4.xml · derivative · entry 5 McKenzie Paul · CIK 0001677903 · EVP Pharmaceutical Oper & Tech 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 280 shares Expires 2019-03-01 F2 · shares: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested. F1 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 21:17 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 568 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-009924 · form4.xml · derivative · entry 4 McKenzie Paul · CIK 0001677903 · EVP Pharmaceutical Oper & Tech 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 280 Underlying: Common Stock · 568 shares Expires 2019-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 21:17 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 253 | $334.10 | $84,527.30 |
DisclosureSEC source: 0001127602-19-009924 · form4.xml · nonDerivative · entry 3 McKenzie Paul · CIK 0001677903 · EVP Pharmaceutical Oper & Tech 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,234.631 Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 21:17 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 568 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-009924 · form4.xml · nonDerivative · entry 2 McKenzie Paul · CIK 0001677903 · EVP Pharmaceutical Oper & Tech 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,487.631 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 21:17 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 405 | $334.10 | $135,310.50 |
DisclosureSEC source: 0001127602-19-009924 · form4.xml · nonDerivative · entry 1 McKenzie Paul · CIK 0001677903 · EVP Pharmaceutical Oper & Tech 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,919.631 Read SEC document |
| February 15, 2019 Filed Feb 20, 2019 23:07 UTC | BIOGEN INC. BIIB · Entity 1675 | OtherRestricted Stock Unit · Derivative | 888 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-007260 · form4.xml · derivative · entry 4 McKenzie Paul · CIK 0001677903 · EVP Pharmaceutical Oper & Tech 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,338 Underlying: Common Stock · 888 shares Expires 2020-02-15 F2 · shares: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested. F1 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). Read SEC document |
| February 15, 2019 Filed Feb 20, 2019 23:07 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 1,448 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-007260 · form4.xml · derivative · entry 3 McKenzie Paul · CIK 0001677903 · EVP Pharmaceutical Oper & Tech 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,226 Underlying: Common Stock · 1,448 shares Expires 2020-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). Read SEC document |
| February 15, 2019 Filed Feb 20, 2019 23:07 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 643 | $332.87 | $214,035.41 |
DisclosureSEC source: 0001127602-19-007260 · form4.xml · nonDerivative · entry 2 McKenzie Paul · CIK 0001677903 · EVP Pharmaceutical Oper & Tech 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,324.631 Read SEC document |
| February 15, 2019 Filed Feb 20, 2019 23:07 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 1,448 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-007260 · form4.xml · nonDerivative · entry 1 McKenzie Paul · CIK 0001677903 · EVP Pharmaceutical Oper & Tech 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,967.631 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 12, 2019 Filed Feb 14, 2019 23:17 UTC | BIOGEN INC. BIIB · Entity 1675 | GrantRestricted Stock Unit · Derivative | 10,960 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-006088 · form4.xml · derivative · entry 8 McKenzie Paul · CIK 0001677903 · EVP Pharmaceutical Oper & Tech 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,960 Underlying: Common Stock · 10,960 shares Expires 2022-02-12 F3 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]). Read SEC document |
| February 12, 2019 Filed Feb 14, 2019 23:17 UTC | BIOGEN INC. BIIB · Entity 1675 | OtherRestricted Stock Unit · Derivative | 1,357 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-006088 · form4.xml · derivative · entry 7 McKenzie Paul · CIK 0001677903 · EVP Pharmaceutical Oper & Tech 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,314 Underlying: Common Stock · 1,357 shares Expires 2021-02-12 F4 · shares: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested. F3 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]). Read SEC document |
| February 12, 2019 Filed Feb 14, 2019 23:17 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 1,799 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-006088 · form4.xml · derivative · entry 6 McKenzie Paul · CIK 0001677903 · EVP Pharmaceutical Oper & Tech 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,671 Underlying: Common Stock · 1,799 shares Expires 2021-02-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]). Read SEC document |
| February 12, 2019 Filed Feb 14, 2019 23:17 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 1,263 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-006088 · form4.xml · derivative · entry 5 McKenzie Paul · CIK 0001677903 · EVP Pharmaceutical Oper & Tech 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,527 Underlying: Common Stock · 1,263 shares Expires 2020-02-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The restricted stock units will vest in 2 annual installments. One-third will vest on the first anniversary of the grant date and two-thirds will vest on the second anniversary of the grant date. Read SEC document |
| February 12, 2019 Filed Feb 14, 2019 23:17 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 539 | $319.43 | $172,172.77 |
DisclosureSEC source: 0001127602-19-006088 · form4.xml · nonDerivative · entry 4 McKenzie Paul · CIK 0001677903 · EVP Pharmaceutical Oper & Tech 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,519.631 Read SEC document |
| February 12, 2019 Filed Feb 14, 2019 23:17 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 1,799 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-006088 · form4.xml · nonDerivative · entry 3 McKenzie Paul · CIK 0001677903 · EVP Pharmaceutical Oper & Tech 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,058.631 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 12, 2019 Filed Feb 14, 2019 23:17 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 380 | $319.43 | $121,383.40 |
DisclosureSEC source: 0001127602-19-006088 · form4.xml · nonDerivative · entry 2 McKenzie Paul · CIK 0001677903 · EVP Pharmaceutical Oper & Tech 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,259.631 Read SEC document |
| February 12, 2019 Filed Feb 14, 2019 23:17 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 1,263 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-006088 · form4.xml · nonDerivative · entry 1 McKenzie Paul · CIK 0001677903 · EVP Pharmaceutical Oper & Tech 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,639.631 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 74.812 shares acquired under the Biogen Inc. employee stock purchase plan on 3/29/2018. Read SEC document |
| March 01, 2018 Filed Mar 5, 2018 21:41 UTC | BIOGEN INC. BIIB · Entity 1675 | OtherRestricted Stock Unit · Derivative | 312 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-010088 · form4.xml · derivative · entry 5 McKenzie Paul · CIK 0001677903 · EVP Pharmaceutical Oper & Tech 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 848 Underlying: Common Stock · 312 shares Expires 2019-03-01 F2 · shares: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested. F1 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). Read SEC document |
| March 01, 2018 Filed Mar 5, 2018 21:41 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 532 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-010088 · form4.xml · derivative · entry 4 McKenzie Paul · CIK 0001677903 · EVP Pharmaceutical Oper & Tech 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,160 Underlying: Common Stock · 532 shares Expires 2019-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). Read SEC document |
| March 01, 2018 Filed Mar 5, 2018 21:41 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 237 | $282.35 | $66,916.95 |
DisclosureSEC source: 0001127602-18-010088 · form4.xml · nonDerivative · entry 3 McKenzie Paul · CIK 0001677903 · EVP Pharmaceutical Oper & Tech 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,301.819 Read SEC document |
| March 01, 2018 Filed Mar 5, 2018 21:41 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 532 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-010088 · form4.xml · nonDerivative · entry 2 McKenzie Paul · CIK 0001677903 · EVP Pharmaceutical Oper & Tech 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,538.819 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 01, 2018 Filed Mar 5, 2018 21:41 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 405 | $282.35 | $114,351.75 |
DisclosureSEC source: 0001127602-18-010088 · form4.xml · nonDerivative · entry 1 McKenzie Paul · CIK 0001677903 · EVP Pharmaceutical Oper & Tech 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,006.819 Read SEC document |
| February 15, 2018 Filed Feb 20, 2018 21:23 UTC | BIOGEN INC. BIIB · Entity 1675 | OtherRestricted Stock Unit · Derivative | 864 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-007206 · form4.xml · derivative · entry 4 McKenzie Paul · CIK 0001677903 · EVP Pharmaceutical Oper & Tech 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,674 Underlying: Common Stock · 864 shares Expires 2020-02-15 F3 · shares: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested. F2 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). Read SEC document |
| February 15, 2018 Filed Feb 20, 2018 21:23 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 1,472 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-007206 · form4.xml · derivative · entry 3 McKenzie Paul · CIK 0001677903 · EVP Pharmaceutical Oper & Tech 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,538 Underlying: Common Stock · 1,472 shares Expires 2020-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). Read SEC document |
| February 15, 2018 Filed Feb 20, 2018 21:23 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 442 | $299.38 | $132,325.96 |
DisclosureSEC source: 0001127602-18-007206 · form4.xml · nonDerivative · entry 2 McKenzie Paul · CIK 0001677903 · EVP Pharmaceutical Oper & Tech 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,411.819 Read SEC document |
| February 15, 2018 Filed Feb 20, 2018 21:23 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 1,472 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-007206 · form4.xml · nonDerivative · entry 1 McKenzie Paul · CIK 0001677903 · EVP Pharmaceutical Oper & Tech 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,853.819 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 56.628 shares, 14.094 shares, 12.029 shares and 7.625 shares acquired under the Biogen Inc. employee stock purchase plan on 3/31/2017, 6/30/2017, 9/29/2017 and 12/29/2017, respectively. Read SEC document |
| February 12, 2018 Filed Feb 14, 2018 23:41 UTC | BIOGEN INC. BIIB · Entity 1675 | GrantRestricted Stock Unit · Derivative | 9,470 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-006186 · form4.xml · derivative · entry 2 McKenzie Paul · CIK 0001677903 · EVP Pharmaceutical Oper & Tech 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,470 Underlying: Common Stock · 9,470 shares Expires 2021-02-12 F2 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]). Read SEC document |
| February 12, 2018 Filed Feb 14, 2018 23:41 UTC | BIOGEN INC. BIIB · Entity 1675 | GrantRestricted Stock Unit · Derivative | 3,790 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-006186 · form4.xml · derivative · entry 1 McKenzie Paul · CIK 0001677903 · EVP Pharmaceutical Oper & Tech 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,790 Underlying: Common Stock · 3,790 shares Expires 2020-02-12 F1 · derivative.exercise_date: The restricted stock units will vest in 2 annual installments. One-third will vest on the first anniversary of the grant date and two-thirds will vest on the second anniversary of the grant date. Read SEC document |
| March 01, 2017 Filed Mar 3, 2017 23:07 UTC | BIOGEN INC. BIIB · Entity 1675 | OtherRestricted Stock Unit · Derivative | 363 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-010305 · form4.xml · derivative · entry 5 McKenzie Paul · CIK 0001677903 · EVP Pharmaceutical Oper & Tech 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,692 Underlying: Common Stock · 363 shares Expires 2019-03-01 F4 · shares: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested. F3 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). Read SEC document |
| March 01, 2017 Filed Mar 3, 2017 23:07 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 481 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-010305 · form4.xml · derivative · entry 4 McKenzie Paul · CIK 0001677903 · EVP Pharmaceutical Oper & Tech 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,055 Underlying: Common Stock · 481 shares Expires 2019-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · shares: This award was previously reported as covering 2,480 shares, but was adjusted pursuant to the anti-dilution provisions of the award in connection with the spin-off of Bioverativ, Inc. on February 1, 2017 F3 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). F2 · derivative.underlying_shares: This award was previously reported as covering 2,480 shares, but was adjusted pursuant to the anti-dilution provisions of the award in connection with the spin-off of Bioverativ, Inc. on February 1, 2017 F2 · balance_after: This award was previously reported as covering 2,480 shares, but was adjusted pursuant to the anti-dilution provisions of the award in connection with the spin-off of Bioverativ, Inc. on February 1, 2017 Read SEC document |
| March 01, 2017 Filed Mar 3, 2017 23:07 UTC | BIOGEN INC. BIIB · Entity 1675 | GrantCommon Stock | 2,730 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-010305 · form4.xml · nonDerivative · entry 3 McKenzie Paul · CIK 0001677903 · EVP Pharmaceutical Oper & Tech 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,291.443 Read SEC document |
| March 01, 2017 Filed Mar 3, 2017 23:07 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 157 | $293.26 | $46,041.82 |
DisclosureSEC source: 0001127602-17-010305 · form4.xml · nonDerivative · entry 2 McKenzie Paul · CIK 0001677903 · EVP Pharmaceutical Oper & Tech 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 561.443 Read SEC document |
| March 01, 2017 Filed Mar 3, 2017 23:07 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 481 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-010305 · form4.xml · nonDerivative · entry 1 McKenzie Paul · CIK 0001677903 · EVP Pharmaceutical Oper & Tech 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 718.443 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 27.114 shares acquired under the Biogen Inc. employee stock purchase plan on 9/30/2016 and 12/30/2016. Read SEC document |
| February 15, 2017 Filed Feb 18, 2017 01:19 UTC | BIOGEN INC. BIIB · Entity 1675 | GrantRestricted Stock Unit · Derivative | 7,010 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-007109 · form4.xml · derivative · entry 1 McKenzie Paul · CIK 0001677903 · EVP Pharmaceutical Oper & Tech 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,010 Underlying: Common Stock · 7,010 shares Expires 2020-02-15 F1 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.